Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE TEN versus PSEUDO 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE TEN versus PSEUDO 12.
DIMETANE-TEN vs PSEUDO-12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane-Ten is a combination of brompheniramine (antihistamine) and phenylephrine (decongestant). Brompheniramine competitively blocks histamine H1 receptors, reducing allergic symptoms; phenylephrine acts as an α1-adrenergic receptor agonist, causing vasoconstriction in nasal mucosa.
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
One tablet (chlorpheniramine maleate 4 mg, phenylephrine HCl 10 mg, methscopolamine nitrate 2.5 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinical context: allows twice-daily dosing; prolonged in renal impairment.
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; remainder as minor pathways.
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Category C
Category C
Decongestant/Antihistamine Combination
Decongestant